Galaxy Medicare (GML)
Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 1/1
Key Financials
| Current Price | ₹18.6 |
| Market Cap | ₹25.79 Cr |
| P/E Ratio | 7.01 |
| ROCE | 17.72% |
| ROE | —% |
| Dividend Yield | 2.06% |
| Profit Growth | 18.13% |
| Debt/Equity | — |
| Sales Growth | 8.64% |
| Promoter Holding | 72.98% |
| 52-Week Range | ₹15.15 — ₹20.45 |
| Sector | Healthcare Equipment & Supplies |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
Galaxy Medicare is exactly the sort of small, out-of-favour name that Graham would ask me to look at—but only after checking the numbers underneath. At ₹18.60, the market cap is just ₹26 crore, so this is a microcap. The P/E of 7.01 is cheap, and with profit growing 18.13% against a PEG of 0.52, the price seems to be paying me for growth rather than making me pay for it. Sales growth of 8.64% is more subdued, so I cannot call it a fast grower. Still, the company earns a 17.72% ROCE, which tells me the existing capital is being used reasonably well, and a Piotroski score of 7/9 suggests a healthy recent financial position. The 2.06% dividend gives a small income shield while I wait.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer